Trial Profile
Treatment plan for the emergency use of SKI-606 in Patients with Imatinib-, Dasatinib-, and Nilotinib- resistant/intolerant Philadelphia Chromosome Positive Leukemias.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2012
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- 21 Jul 2009 New trial record.